Ataraxis AI unveils models for cancer treatment prediction. Ataraxis AI announced a new generation of models built to predict treatment response and patient outcomes, with an initial focus on breast cancer and broader testing across solid tumors. The company said the models can generalize zero-shot from breast cancer to multiple solid tumors, positioning the work as a step toward more personalized oncology treatment planning. The company is releasing three research papers, including a study on causal AI methods applied to predicting chemotherapy benefit and patient outcomes in breast cancer. The study covers 11,135 patients across 17 cohorts, followed by zero-shot generalization in 6,692 patients across 16 cancer types. Two additional papers report clinical validation in TAILORx Phase III trial and UNIRAD Phase III trial. Ataraxis said TAILORx Phase III trial results confirmed statistically significant chemotherapy benefit predictions, while UNIRAD Phase III trial findings showed predictions of outcomes and treatment benefit in high-risk breast cancer, including benefit from everolimus. The models are based on causal AI methods that learn to simulate patient outcomes under counterfactual scenarios using longitudinal data. Ataraxis has incorporated those methods into Ataraxis Tau, an AI world model intended to support future tools for building personalized treatment plans across oncology. Originally reported by oncodaily.com Read the source

Ataraxis AI has raised $20.4 million in a Series A round led by AIX Ventures to commercialise its cancer treatment prediction technology. Thiel Bio, Founders Fund, Floating Point, Bertelsmann, Giant Ventures and Obvious Ventures also participated. The company previously raised $4 million in seed funding. The startup analyses high-resolution images of cancer cells using AI trained on hundreds of millions of images from thousands of patients. According to Ataraxis, its technology is 30% more accurate than current standards for breast cancer care. The funding will support the commercial launch of its first breast cancer test and expansion into other cancer types. Co-founded by Jan Witowski and NYU professor Krzysztof Geras, Ataraxis aims to help predict long-term cancer outcomes and potentially reduce unnecessary chemotherapy treatments.